François Radvanyi is a research director at CNRS, specializing in the genetics and epigenetics of cancer. His approach combines bioinformatics and experimental validation.
He completed his thesis at the Pasteur Institute under the direction of Cassian Bon and a post-doctoral internship at the Hormone Research Institute, UCSF, San Francisco under the direction of Douglas Hanahan. His team, initially created within the unit of Jean Paul Thiery at ENS, is now located at the Curie Institute (Molecular Oncology Team, UMR 144 CNRS).
The cancers studied by the team include a common adult cancer, bladder cancer, and a pediatric cancer treated at the Curie Institute, retinoblastoma. Their work is multidisciplinary and involves MDs, biologists, epidemiologists, and bioinformaticians.
Some of their notable results include the identification of key genes in bladder cancers, such as the FGFR3, EGFR, and TYRO3 tyrosine kinase receptors, and the PPARG nuclear receptor; characterization of bladder cancer subtypes, particularly the basal subtype; and characterization of an aggressive subset of retinoblastoma. Their discoveries have led to several clinical applications.